# TG Therapeutics

Source: https://onco.cc/companies/tg-therapeutics/  
OnCo record `tg-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TG Therapeutics is a New York company whose lymphoma drug umbralisib was approved in 2021 and withdrawn in 2022 over a survival signal, and which now sells the anti-CD20 antibody ublituximab for multiple sclerosis.

## Summary

TG Therapeutics, listed on Nasdaq, developed the PI3K-delta and CK1-epsilon inhibitor umbralisib (Ukoniq), which received accelerated approval in 2021 for relapsed marginal zone and follicular lymphoma and was withdrawn in 2022 after the UNITY-CLL trial suggested a possible detriment in overall survival, and the glycoengineered anti-CD20 antibody ublituximab, which it had studied with umbralisib in chronic lymphocytic leukaemia and which is now approved as Briumvi for relapsing multiple sclerosis. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: TG Therapeutics, Inc.
- Tags: ctgov-sponsor
- HQ: New York, NY
- Type: biotech
- Website: https://www.tgtherapeutics.com

## Sources

- Official website: https://www.tgtherapeutics.com
- ClinicalTrials.gov: trials led by TG Therapeutics: https://clinicaltrials.gov/search?lead=TG%20Therapeutics
- Wikipedia: https://en.wikipedia.org/wiki/TG_Therapeutics

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [CD20](https://onco.cc/targets/cd20/), [PI3K delta (PIK3CD)](https://onco.cc/targets/pik3cd/)
- drugs: [Umbralisib](https://onco.cc/drugs/umbralisib/)

---
JSON: https://onco.cc/api/v1/entities/tg-therapeutics.json